Regenosca SA
Regenosca is a biotech company specializing in creating innovative bio-implants that enable the body to attract and organize its own cells for seamless tissue healing. Their TissueSpan technology forms a temporary, naturally-absorbed bridge after removal of diseased tissue, aiming to restore patients to full health. The company focuses on natural, regenerative surgical interventions with applications in urology and organ repair, with ongoing clinical trials and partnerships. They have received multiple awards, patents, and certifications, and actively participate in industry conferences and research publications.
Industries
Nr. of Employees
small (1-50)
Products
Resorbable tissue-regenerative mesh implant
A temporary, absorbable mesh scaffold engineered to recruit host cells and enable tissue regeneration after removal of diseased tissue; intended as an off-the-shelf alternative to autologous grafts for soft-tissue reconstruction.
Resorbable tissue-regenerative mesh implant
A temporary, absorbable mesh scaffold engineered to recruit host cells and enable tissue regeneration after removal of diseased tissue; intended as an off-the-shelf alternative to autologous grafts for soft-tissue reconstruction.
Services
Planning, regulatory coordination, site collaboration, recruitment and operational support for first-in-human and pilot clinical studies assessing implant safety and performance.
Development and production of GMP-compliant prototype implants and design of local manufacturing capabilities to support scale-up and regulatory filings.
Collaborative research agreements with academic groups and clinical centres to generate preclinical and clinical evidence supporting device translation and regulatory submissions.
Planning, regulatory coordination, site collaboration, recruitment and operational support for first-in-human and pilot clinical studies assessing implant safety and performance.
Development and production of GMP-compliant prototype implants and design of local manufacturing capabilities to support scale-up and regulatory filings.
Collaborative research agreements with academic groups and clinical centres to generate preclinical and clinical evidence supporting device translation and regulatory submissions.
Expertise Areas
- Tissue engineering and regenerative implants
- Biomaterials development (resorbable collagen scaffolds)
- Preclinical testing and biocompatibility assessment
- Clinical trial initiation and first-in-human studies
Key Technologies
- Resorbable collagen scaffold fabrication
- Biodegradable mesh implant design
- Endoscopic delivery systems for implants
- In vitro cell and tissue assay methods
News & Updates
Publication of Regenosca’s preclinical paper in the journal Urology, showcasing the successful collaboration and potential of TissueSpan technology.
Regenosca closes CHF 1 million pre-seed funding to demonstrate endoscopic delivery of TissueSpan implants.
Aydin Kurt-Elli appointed as a new board member, bringing entrepreneurial experience and a healthcare network.
Regenosca obtained the Innosuisse certificate after completing the core coaching program, validating their business strategy and regulatory readiness.
Networking event in Boston with Swiss startups, investors, and experts, showcasing Regenosca’s innovation.
Dr Ganesh Vythilingam received a moderated poster award for Regenosca’s TissueSpan technology at the American Urology Association conference.
Publication of Regenosca’s preclinical paper in the journal Urology, showcasing the successful collaboration and potential of TissueSpan technology.
Regenosca closes CHF 1 million pre-seed funding to demonstrate endoscopic delivery of TissueSpan implants.
Aydin Kurt-Elli appointed as a new board member, bringing entrepreneurial experience and a healthcare network.
Regenosca obtained the Innosuisse certificate after completing the core coaching program, validating their business strategy and regulatory readiness.
Networking event in Boston with Swiss startups, investors, and experts, showcasing Regenosca’s innovation.
Dr Ganesh Vythilingam received a moderated poster award for Regenosca’s TissueSpan technology at the American Urology Association conference.